| GSE5287 | Bladder cancer | | Overall Survival | Aarhus (1995-2004) | Als | HG-U133A | 30 |
| GSE13507 | Bladder cancer | | Overall Survival | CNUH | Kim | Human-6 v2 | 165 |
| GSE13507 | Bladder cancer | Transitional cell carcinoma | Disease Specific Survival | CNUH | Kim | Human-6 v2 | 165 |
| GSE12417-GPL96 | Blood cancer | AML | Overall Survival | AMLCG (1999-2003) | Metzeler | HG-U133A | 163 |
| GSE12417-GPL97 | Blood cancer | AML | Overall Survival | AMLCG (1999-2003) | Metzeler | HG-U133B | 163 |
| GSE12417-GPL570 | Blood cancer | AML | Overall Survival | AMLCG (2004) | Metzeler | HG-U133_Plus_2 | 79 |
| GSE5122 | Blood cancer | AML | Overall Survival | San Diego | Raponi | HG-U133A | 58 |
| GSE8970 | Blood cancer | AML | Overall Survival | San Diego | Raponi | HG-U133A | 34 |
| GSE4475 | Blood cancer | B-cell lymphoma | Overall Survival | Berlin (2003-2005) | Hummel | HG-U133A | 158 |
| E-TABM-346 | Blood cancer | DLBCL | Event Free Survival | GELA (1998-2000) | Jais | HG-U133A | 53 |
| E-TABM-346 | Blood cancer | DLBCL | Overall Survival | GELA (1998-2000) | Jais | HG-U133A | 53 |
| GSE16131-GPL96 | Blood cancer | Follicular lymphoma | Overall Survival | NCI (1974-2001) | Dave | HG-U133A | 180 |
| GSE16131-GPL97 | Blood cancer | Follicular lymphoma | Overall Survival | NCI (1974-2001) | Dave | HG-U133B | 180 |
| GSE2658 | Blood cancer | Multiple myeloma | Disease Specific Survival | Arkansas | Zhan | HG-U133_Plus_2 | 559 |
| GSE4271-GPL96 | Brain cancer | Astrocytoma | Overall Survival | MDA | Phillips | HG-U133A | 77 |
| GSE4271-GPL97 | Brain cancer | Astrocytoma | Overall Survival | MDA | Phillips | HG-U133B | 77 |
| GSE7696 | Brain cancer | Glioblastoma | Overall Survival | Lausanne | Murat | HG-U133_Plus_2 | 70 |
| MGH-glioma | Brain cancer | Glioma | Overall Survival | CBTTB, MGH, BWH, CH | Nutt | HG-U95A | 50 |
| GSE4412-GPL96 | Brain cancer | Glioma | Overall Survival | UCLA (1996-2003) | Freije | HG-U133A | 74 |
| GSE4412-GPL97 | Brain cancer | Glioma | Overall Survival | UCLA (1996-2003) | Freije | HG-U133B | 74 |
| GSE16581 | Brain cancer | Meningioma | Overall Survival | UCLA | Lee | HG-U133_Plus_2 | 67 |
| GSE19615 | Breast cancer | | Distant Metastasis Free Survival | DF/HCC | Li | HG-U133_Plus_2 | 115 |
| GSE3143 | Breast cancer | | Overall Survival | Duke | Bild | HG-U95A | 158 |
| GSE7849 | Breast cancer | | Disease Free Survival | Duke (1990-2001) | Anders | HG-U95A | 76 |
| GSE12276 | Breast cancer | | Relapse Free Survival | EMC | Bos | HG-U133_Plus_2 | 204 |
| GSE6532-GPL570 | Breast cancer | | Relapse Free Survival | GUYT | Loi | HG-U133_Plus_2 | 87 |
| GSE6532-GPL570 | Breast cancer | | Distant Metastasis Free Survival | GUYT | Loi | HG-U133_Plus_2 | 87 |
| GSE9195 | Breast cancer | | Distant Metastasis Free Survival | GUYT2 | Loi | HG-U133_Plus_2 | 77 |
| GSE9195 | Breast cancer | | Relapse Free Survival | GUYT2 | Loi | HG-U133_Plus_2 | 77 |
| GSE12093 | Breast cancer | | Distant Metastasis Free Survival | IO, NCI, TUM, CCF (1992-2000) | Zhang | HG-U133A | 136 |
| GSE11121 | Breast cancer | | Distant Metastasis Free Survival | Mainz (1988-1998) | Schmidt | HG-U133A | 200 |
| GSE1378 | Breast cancer | | Relapse Free Survival | MGH (1987-2000) | Ma | Arcturus 22k | 60 |
| GSE1379 | Breast cancer | | Relapse Free Survival | MGH (1987-2000) | Ma | Arcturus 22k | 60 |
| GSE9893 | Breast cancer | | Overall Survival | Montpellier, Bordeaux, Turin (1989-2001) | Chanrion | MLRG Human 21K V12.0 | 155 |
| GSE2034 | Breast cancer | | Distant Metastasis Free Survival | Rotterdam (1980-1995) | Wang | HG-U133A | 286 |
| GSE1456-GPL96 | Breast cancer | | Overall Survival | Stockholm (1994-1996) | Pawitan | HG-U133A | 159 |
| GSE1456-GPL96 | Breast cancer | | Relapse Free Survival | Stockholm (1994-1996) | Pawitan | HG-U133A | 159 |
| GSE1456-GPL96 | Breast cancer | | Disease Specific Survival | Stockholm (1994-1996) | Pawitan | HG-U133A | 159 |
| GSE1456-GPL97 | Breast cancer | | Disease Specific Survival | Stockholm (1994-1996) | Pawitan | HG-U133B | 159 |
| GSE1456-GPL97 | Breast cancer | | Relapse Free Survival | Stockholm (1994-1996) | Pawitan | HG-U133B | 159 |
| GSE1456-GPL97 | Breast cancer | | Overall Survival | Stockholm (1994-1996) | Pawitan | HG-U133B | 159 |
| GSE7378 | Breast cancer | | Disease Free Survival | UCSF | Zhou | U133AAofAv2 | 54 |
| E-TABM-158 | Breast cancer | | Overall Survival | UCSF, CPMC (1989-1997) | Chin | HG-U133A | 117 |
| E-TABM-158 | Breast cancer | | Relapse Free Survival | UCSF, CPMC (1989-1997) | Chin | HG-U133A | 117 |
| E-TABM-158 | Breast cancer | | Disease Specific Survival | UCSF, CPMC (1989-1997) | Chin | HG-U133A | 117 |
| E-TABM-158 | Breast cancer | | Distant Metastasis Free Survival | UCSF, CPMC (1989-1997) | Chin | HG-U133A | 117 |
| GSE3494-GPL96 | Breast cancer | | Disease Specific Survival | Uppsala (1987-1989) | Miller | HG-U133A | 236 |
| GSE3494-GPL97 | Breast cancer | | Disease Specific Survival | Uppsala (1987-1989) | Miller | HG-U133B | 236 |
| GSE4922-GPL96 | Breast cancer | | Disease Free Survival | Uppsala (1987-1989) | Ivshina | HG-U133A | 249 |
| GSE4922-GPL97 | Breast cancer | | Disease Free Survival | Uppsala (1987-1989) | Ivshina | HG-U133B | 249 |
| GSE2990 | Breast cancer | | Relapse Free Survival | Uppsala, Oxford | Sotiriou | HG-U133A | 125 |
| GSE2990 | Breast cancer | | Distant Metastasis Free Survival | Uppsala, Oxford | Sotiriou | HG-U133A | 125 |
| GSE2990 | Breast cancer | | Relapse Free Survival | Uppsala, Oxford | Sotiriou | HG-U133A | 62 |
| GSE2990 | Breast cancer | | Distant Metastasis Free Survival | Uppsala, Oxford | Sotiriou | HG-U133A | 54 |
| GSE7390 | Breast cancer | | Relapse Free Survival | Uppsala, Oxford, Stockholm, IGR, GUYT, CRH (1980-1998) | Desmedt | HG-U133A | 198 |
| GSE7390 | Breast cancer | | Distant Metastasis Free Survival | Uppsala, Oxford, Stockholm, IGR, GUYT, CRH (1980-1998) | Desmedt | HG-U133A | 198 |
| GSE7390 | Breast cancer | | Overall Survival | Uppsala, Oxford, Stockholm, IGR, GUYT, CRH (1980-1998) | Desmedt | HG-U133A | 198 |
| GSE12945 | Colorectal cancer | | Overall Survival | Berlin | Staub | HG-U133A | 62 |
| GSE12945 | Colorectal cancer | | Disease Free Survival | Berlin | Staub | HG-U133A | 51 |
| GSE17536 | Colorectal cancer | | Disease Free Survival | MCC | Smith | HG-U133_Plus_2 | 145 |
| GSE17536 | Colorectal cancer | | Overall Survival | MCC | Smith | HG-U133_Plus_2 | 177 |
| GSE17536 | Colorectal cancer | | Disease Specific Survival | MCC | Smith | HG-U133_Plus_2 | 177 |
| GSE14333 | Colorectal cancer | | Disease Free Survival | Melbourne | Jorissen | HG-U133_Plus_2 | 226 |
| GSE17537 | Colorectal cancer | | Overall Survival | VMC | Smith | HG-U133_Plus_2 | 55 |
| GSE17537 | Colorectal cancer | | Disease Specific Survival | VMC | Smith | HG-U133_Plus_2 | 49 |
| GSE17537 | Colorectal cancer | | Disease Free Survival | VMC | Smith | HG-U133_Plus_2 | 55 |
| GSE11595 | Esophagus cancer | Adenocarcinoma | Overall Survival | Sutton | Giddings | CRUKDMF_22K_v1.0.0 | 34 |
| GSE22138 | Eye cancer | Uveal melanoma | Distant Metastasis Free Survival | BRCIC | Laurent | HG-U133_Plus_2 | 63 |
| GSE2837 | Head and neck cancer | Squamous cell carcinoma | Relapse Free Survival | VUMC, VAMC, UTMDACC (1992-2005) | Chung | U133_X3P | 28 |
| jacob-00182-CANDF | Lung cancer | Adenocarcinoma | Overall Survival | CAN/DF | Shedden | HG-U133A | 82 |
| HARVARD-LC | Lung cancer | Adenocarcinoma | Overall Survival | Harvard | Beer | HG-U95A | 84 |
| jacob-00182-HLM | Lung cancer | Adenocarcinoma | Overall Survival | HLM | Shedden | HG-U133A | 79 |
| MICHIGAN-LC | Lung cancer | Adenocarcinoma | Overall Survival | Michigan (1994-2000) | Beer | HuGeneFL | 86 |
| jacob-00182-MSK | Lung cancer | Adenocarcinoma | Overall Survival | MSK | Shedden | HG-U133A | 104 |
| GSE13213 | Lung cancer | Adenocarcinoma | Overall Survival | Nagoya (1995-1999, 2002-2004) | Tomida | G4112F | 117 |
| GSE31210 | Lung cancer | Adenocarcinoma | Overall Survival | NCCRI | Okayama | HG-U133_Plus_2 | 204 |
| GSE31210 | Lung cancer | Adenocarcinoma | Relapse Free Survival | NCCRI | Okayama | HG-U133_Plus_2 | 204 |
| jacob-00182-UM | Lung cancer | Adenocarcinoma | Overall Survival | UM | Shedden | HG-U133A | 178 |
| GSE11117 | Lung cancer | NSCLC | Overall Survival | Basel (2002-2005) | Baty | Novachip human 34.5k | 41 |
| GSE3141 | Lung cancer | NSCLC | Overall Survival | Duke | Bild | HG-U133_Plus_2 | 111 |
| GSE14814 | Lung cancer | NSCLC | Overall Survival | JRB.10 | Zhu | HG-U133A | 90 |
| GSE14814 | Lung cancer | NSCLC | Disease Specific Survival | JRB.10 | Zhu | HG-U133A | 90 |
| GSE4716-GPL3694 | Lung cancer | NSCLC | Overall Survival | Nagoya (1995-1996) | Tomida | GF200 | 50 |
| GSE4716-GPL3696 | Lung cancer | NSCLC | Overall Survival | Nagoya (1995-1996) | Tomida | GF201 | 50 |
| GSE8894 | Lung cancer | NSCLC | Relapse Free Survival | Seoul (1995-2005) | Lee | HG-U133_Plus_2 | 138 |
| GSE4573 | Lung cancer | Squamous cell carcinoma | Overall Survival | Michigan (1991-2002) | Raponi | HG-U133A | 129 |
| GSE17710 | Lung cancer | Squamous cell carcinoma | Relapse Free Survival | UNC | Wilkerson | Agilent-UNC-custom-4X44K | 56 |
| GSE17710 | Lung cancer | Squamous cell carcinoma | Overall Survival | UNC | Wilkerson | Agilent-UNC-custom-4X44K | 56 |
| GSE9891 | Ovarian cancer | | Overall Survival | AOCS, RBH, WH, NKI-AVL (1992-2006) | Tothill | HG-U133_Plus_2 | 278 |
| DUKE-OC | Ovarian cancer | | Overall Survival | Duke | Bild | HG-U133A | 133 |
| GSE8841 | Ovarian cancer | | Overall Survival | Milan (1992-2003) | Marchini | G4100A | 81 |
| GSE26712 | Ovarian cancer | | Overall Survival | MSKCC (1990-2003) | Bonome | HG-U133_Plus_2 | 185 |
| GSE26712 | Ovarian cancer | | Disease Free Survival | MSKCC (1990-2003) | Bonome | HG-U133_Plus_2 | 185 |
| GSE17260 | Ovarian cancer | | Progression Free Survival | Niigata (1997-2008) | Yoshihara | G4112A | 110 |
| GSE17260 | Ovarian cancer | | Overall Survival | Niigata (1997-2008) | Yoshihara | G4112A | 110 |
| GSE14764 | Ovarian cancer | | Overall Survival | TOC | Denkert | HG-U133A | 80 |
| GSE16560 | Prostate cancer | | Overall Survival | Sweden (1977-1999) | Sboner | 6K DASL | 281 |
| E-DKFZ-1 | Renal cell carcinoma | | Overall Survival | RZPD | Sueltmann | A-RZPD-20 | 59 |
| GSE19234 | Skin cancer | Melanoma | Overall Survival | NYU | Bogunovic | HG-U133_Plus_2 | 38 |
| GSE30929 | Soft tissue cancer | Liposarcoma | Distant Recurrence Free Survival | MSKCC (1993-2008) | Gobble | HG-U133A | 140 |